Key Takeaways

• Entropy Neurodynamics (ASX:ENP) has secured South African Patent No. 2025/01722 for its psilocybin- and psilocin-based fibromyalgia treatment, with protection running to September 2043.

• The patent covers treatment methods, dosing regimens, patient-selection criteria, clinical protocols, biomarkers and manufacturing processes, not just a single molecule.

• The company, formerly Tryptamine Therapeutics and before that Exopharm, is developing TRP-8803, a proprietary intravenously infused psilocin formulation, as its lead asset.

• Fibromyalgia sits alongside binge eating disorder and irritable bowel syndrome in a psychedelic pipeline that has produced encouraging early Phase 2a signals.

• Investors should watch further patent grants, Phase 2 TRP-8803 data due in Q4 2026, and the company's funding position as it advances toward larger trials.

Entropy Neurodynamics (ASX:ENP) has strengthened the intellectual-property foundations of its psychedelic-medicine pipeline, announcing the grant of a South African patent covering its psilocybin- and psilocin-based approach to treating fibromyalgia. The award adds another jurisdiction to a global patent estate the clinical-stage biotechnology company is steadily assembling around one of the most persistent and poorly served conditions in chronic-pain medicine.

For a small-cap developer at the frontier of psychedelic therapeutics, patents are more than legal housekeeping — they define the commercial moat around programs that can take years and considerable capital to bring through the clinic. The South African grant, which runs to 2043, shows Entropy is thinking about protection well beyond its home market, and doing so before its lead candidate has reached the pivotal-trial stage.

What Has Happened

Entropy Neurodynamics has been granted South African Patent No. 2025/01722, protecting the use of psilocybin and psilocin in the treatment of fibromyalgia. According to the company, the patent's protection extends to 11 September 2043.

Crucially, the grant is broad in scope. Rather than covering a single molecule, it protects treatment methods, dosing regimens, patient-selection criteria, clinical protocols, biomarkers, outcome measures and manufacturing processes tied to the fibromyalgia indication. That breadth matters in psychedelic medicine, where the active compounds are naturally occurring and long known — so the defensible innovation typically lies in how a therapy is formulated, dosed, delivered and measured rather than in the base chemistry.

Management framed the grant as one step in building a robust global patent estate spanning multiple jurisdictions and indications. Chief executive Jason Carroll pointed to the strategic significance of protecting the company's methods across key markets. Entropy has cited the South African fibromyalgia treatment market as worth roughly US$1.9 billion in 2025, indicating why it sees value in securing rights there even though it is not an obvious first launch market.

Why It Matters

Fibromyalgia is a chronic condition characterised by widespread musculoskeletal pain, fatigue, sleep disturbance and cognitive difficulties. It is common — the company has noted it affects roughly one million Australians — yet existing treatments are limited, often only partially effective, and can carry significant side-effect burdens. That combination of high prevalence and poor standard of care is the gap a differentiated therapy could address.

For Entropy, the patent does two things. It lengthens and widens the runway of protection around a program the company hopes to advance into later-stage trials — essential for attracting the partners and capital that clinical development requires. And it signals discipline: securing IP across multiple geographies before commercialisation is standard practice for serious drug developers, distinguishing a company building durable assets from one chasing psychedelic headlines.

It is worth being clear about what the grant is not. A patent protects an invention; it does not prove a therapy works, nor is it a regulatory approval. Entropy still has to generate the clinical evidence and navigate approval pathways before any fibromyalgia product could reach patients.

From Exopharm to Entropy: The Pipeline Behind the Patent

Entropy Neurodynamics is a new name for a company with a layered history. It was previously Tryptamine Therapeutics, and before that Exopharm — the ASX-listed business that acquired psychedelic developer Tryp Therapeutics and reoriented itself around psilocybin-based medicine. The rebrand took effect on 21 November 2025, following shareholder approval on 13 November 2025.

The new identity is deliberate. It draws on the "entropic brain" hypothesis — the idea that psychedelics increase the variability, or entropy, of spontaneous brain activity, nudging neural systems toward a more flexible state. Management has framed the rebrand as an evolution from pure psychedelic drug development toward a broader, biomarker-driven neuropsychiatry platform.

The Lead Asset: TRP-8803

At the centre of the pipeline is TRP-8803, a proprietary, intravenously infused formulation of psilocin — the active metabolite that psilocybin converts to in the body. Delivering psilocin directly by IV is intended to give clinicians tighter control over the onset, depth and duration of the psychedelic experience than an oral capsule allows, potentially shortening dosing sessions. The company has paired this with real-time EEG monitoring to correlate psilocin blood levels with the depth of the psychedelic state — an approach it describes as a first for the field.

A Multi-Indication Strategy

Entropy's pipeline spans several conditions. Alongside fibromyalgia, the company has pursued Phase 2a work in binge eating disorder and irritable bowel syndrome. Much of the early signal came from studies using TRP-8802, an oral psilocybin formulation — the strategy being to demonstrate proof of concept orally before transitioning indications to the differentiated IV candidate, TRP-8803.

Key Financial and Operational Details

The fibromyalgia patent is grounded in real clinical work. A Phase 2a study of TRP-8802 in fibromyalgia was conducted with the University of Michigan, with researchers presenting results at the International Association for the Study of Pain 2024 World Congress in the Netherlands. The company reported that psilocybin-assisted therapy produced positive effects across pain, pain interference, sleep, fatigue and anxiety, although it has been candid that the study was small and detailed efficacy percentages were limited.

Entropy's most advanced current work is a Phase 2 trial of TRP-8803 in treatment-resistant binge eating disorder. In results announced on 7 July 2026, the first cohort showed 50% of patients achieving complete clinical remission, 100% achieving a clinically meaningful improvement, and a 74% reduction in weekly binge-eating episodes, alongside sizeable reductions in anxiety and depression scores. A second cohort was reported fully enrolled, with dosing expected around August 2026 and final Phase 2 results anticipated in the fourth quarter of 2026.

On the market side, ENP remains a micro-cap, with the stock reported trading around A$0.034 in early July 2026. As with any pre-revenue clinical-stage biotech, the share price is highly sensitive to trial readouts and can move sharply in either direction.

Potential Catalysts

Several developments could influence sentiment. The most immediate are further clinical readouts, including the biomarker and EEG analyses from the binge eating disorder program and the final Phase 2 results due in Q4 2026, which would help validate the IV psilocin platform across indications. Additional patent grants in other jurisdictions would extend the IP story the South African award continues, while any move to fund a larger, later-stage fibromyalgia trial — or partnering interest from larger players — would be significant.

Material Risks and Uncertainties

The risks are substantial and typical of the sector. Early-stage trial results — particularly from small studies — do not always replicate in larger, controlled trials, and fibromyalgia has a long history of therapies that showed early promise but disappointed at scale. Psychedelic medicines also face a complex and evolving regulatory environment, with uncertain approval timelines.

As a pre-revenue developer, Entropy depends on capital markets to fund its programs, raising the prospect of further raisings and dilution. The patent, while valuable, protects methods rather than guaranteeing a commercial product, and its worth ultimately depends on the underlying therapy succeeding. Competition in the psychedelic and chronic-pain space is intensifying. Investors should treat management's market-size figures and pipeline timelines as guidance rather than certainties.

What Investors Should Watch Next

For Entropy Neurodynamics (ASX:ENP), the near-term signposts are reasonably clear. First, watch the final Phase 2 TRP-8803 results in binge eating disorder due in Q4 2026, along with the supporting EEG and biomarker analyses, as these will test the core platform thesis. Second, look for further patent grants that would broaden the global estate beyond South Africa. Third, monitor any concrete steps toward a larger fibromyalgia trial, since that is the program the new patent directly protects. Investors should also watch the balance sheet and cash runway, and the regulatory landscape for psychedelic therapies.